Maheshwari Anshul sold $56K of SIBN

Maheshwari Anshul (Chief Financial Officer) sold 3,317 shares of SI-BONE, Inc. (SIBN) at an average of $16.77 ($16.73–$16.80) across 2 trades on 2026-07-02.

Original reporting
SEC EDGAR · Maheshwari Anshul
Published Jul 6, 2026, 9:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SIBN
Neutral
high confidence
Mentioned
$SIBN
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SIBNNeutralLow
01

Why it matters

The newest information is the CFO’s open-market sale details (date, shares, price range, and post-transaction holdings).

02

Market read

Traders may monitor insider activity as a sentiment datapoint, but the filing alone does not provide a fundamental catalyst.

03

What to watch

The text notes no pre-arranged 10b5-1 plan, which can raise scrutiny, but the article provides no context on prior grants, tax obligations, or total insider compensation.

Relevance 3/10Novelty 5/10Timing: after-hours/filing update (Form 4 filed 2026-07-06)

Background

The article is a SEC Form 4 insider transaction disclosure for SI-BONE, Inc. (SIBN).

Company-level read

Ticker impact

$SIBNNeutralHigh confidence
Context

SI-BONE CFO Maheshwari Anshul sold 3,317 shares in open-market transactions at ~$16.77, per a newly filed Form 4.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any impact would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a disclosed open-market sale with no 10b5-1 plan and no accompanying fundamental update in the text, making it more of a positioning datapoint than a catalyst.

Market effects

No sector-wide implications disclosed; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or scheduled liquidity needs rather than bearish fundamentals—especially when the transaction size is modest relative to typical insider holdings.

Key entities

  • SI-BONE, Inc.

    Company whose CFO insider sale is disclosed via Form 4.

  • Maheshwari Anshul

    Chief Financial Officer who sold 3,317 shares in open-market transactions.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

$SIBNMed

SI-BONE (SIBN) Q3 2026 Earnings Call Transcript

SI-BONE (SIBN) reported Q3 2026 earnings, highlighting 27% international revenue growth and 32% adjusted EBITDA increase. The company launched iFuse Granite Onyx, expanding its market to 650,000 procedures and $5B opportunity. Onyx targets spinal fusion failure points, with early demand exceeding expectations. New DRGs and reimbursement enhancements support growth. The company expects 20%+ revenue growth in Q4 2026.

$SIBNMed

SiBone Q3 Earnings Call Highlights

SiBone (SIBN) reported Q3 earnings, highlighting strong demand for its Onyx platform, which targets a $1.5B market. Gross profit rose 13.7% to $44.2M, with gross margin at 79.3%. Net loss narrowed to $3.6M. The company reaffirmed 2026 revenue guidance of $231M-$233M and expects Q4 momentum from physician growth and new products.